Breaking Finance News

Zacks Investment Research disclosed Applied Genetic Technologies Corp (NASDAQ:AGTC), bumping up its stock price target to $11.00 today

Just yesterday Applied Genetic Technologies Corp (NASDAQ:AGTC) traded -2.60% lower at $9.35. Applied Genetic Technologies Corp’s 50-day moving average is $10.99 and its 200-day moving average is $14.32. The last stock price is down -34.71% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 102,887 shares of AGTC traded hands, down from an average trading volume of 188,320

In a report released on 10/11/2016 Zacks Investment Research increased the stock price target of Applied Genetic Technologies Corp (NASDAQ:AGTC) to $11.00 reporting a possible upside of 0.18%.

Recent Performance Chart

Applied Genetic Technologies Corp (NASDAQ:AGTC)

Applied Genetic Technologies Corp has 52 week low of $8.50 and a 52 week high of $21.43 and has a market capitalization of $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 5 brokerages have issued a ratings update on the company. The average stock price target is $31.20 with 0 brokerages rating the stock a strong buy, 0 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Applied Genetic Technologies Corp (NASDAQ:AGTC)

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.